BOUNDLESS BIO, INC. Capital Expenditures
BOUNDLESS BIO, INC. (BOLD) reported Capital Expenditures of $46.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-07
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $38.00K, a 20.83% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $8.00K, a 86.44% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $424.00K, a 9.01% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $15.00K, a 96.89% decline year-over-year.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $546.00K, a 78.47% decline from fiscal 2024.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $2.54M, a 300.63% increase from fiscal 2023.
- BOUNDLESS BIO, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $633.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $46.00K 10-Q · filed 2026-08-07 | $470.00K derived: sum of 3 quarters · filed 2026-08-07 | $485.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-08 | $432.00K derived: sum of 2 quarters · filed 2026-05-08 | $447.00K derived: sum of 3 quarters · filed 2026-05-08 | $495.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $439.00K derived: sum of 2 quarters · filed 2026-03-09 | $487.00K derived: sum of 3 quarters · filed 2026-08-07 | $546.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $63.00K derived: sum of 2 quarters · filed 2026-08-07 | $122.00K 10-Q · filed 2025-11-05 | $588.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $107.00K 10-Q · filed 2026-08-07 | $573.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.06M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $59.00K 10-Q · filed 2026-05-08 | $525.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.01M derived: sum of 3 quarters · filed 2026-05-08 | $2.51M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $949.00K derived: sum of 2 quarters · filed 2026-03-09 | $2.45M derived: sum of 3 quarters · filed 2026-03-09 | $2.54M 10-K · filed 2026-03-09 |
| 2024-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.99M derived: sum of 2 quarters · filed 2025-11-05 | $2.07M 10-Q · filed 2025-11-05 | $2.34M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.59M 10-Q · filed 2025-08-05 | $1.85M derived: sum of 3 quarters · filed 2025-08-05 | $2.01M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $83.00K 10-Q · filed 2025-05-09 | $351.00K derived: sum of 2 quarters · filed 2025-05-09 | $502.00K derived: sum of 3 quarters · filed 2025-05-09 | $630.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $419.00K derived: sum of 2 quarters · filed 2025-03-27 | $547.00K derived: sum of 3 quarters · filed 2025-03-27 | $633.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $279.00K derived: sum of 2 quarters · filed 2024-11-07 | $365.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $214.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $86.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |